Arecor and GlaxoSmithKline have entered into a license agreement to develop advanced formulations of vaccines combining Arecor’s formulation technologies with GSK’s proprietary vaccines. GSK and Arecor will work to develop new approaches that could offer significant improvements to the administration of several vaccines in development. Arecor will receive payments on relevant development milestones and royalties on sales. Tom Saylor, chief executive officer of Arecor, said, “Arecor is pleased t...